R&D Strategy & Pipeline

R&D Strategy & Pipeline

R&D Strategy & Pipeline

Committed to innovation, Da Volterra develops microbiota protecting therapies as well as tools intended to harness potential to help prevent and cure human diseases.

Products DiscoveryPreclinicalPhase 1Phase 2Phase 3Market
DAV132Prevention of C. difficile infection in patients with a history of CDI      
Prevention of C. difficile infection & acute graft-versus-host disease (GvHD) in patients with hematologic malignancies    
Add-on therapy to preserve the efficacy of immune checkpoint inhibitors (ICI) in cancer patients   
DID ProgramReduction of severe diarrheas (Grade 3-4) and other consequences due to chemotherapy-induced disruption of the microbiota   
Microbiome Discovery PlatformNew microbiome diagnostic tests, predictive of clinical manifestations of dysbiosis  
Novel microbiome-targeted protective and interventional therapies 

Over the years since inception, we have gathered a unique in-house expertise on the intestinal microbiota and its links to the different body functions, antibacterial drugs and other drugs disrupting the microbiota as well as drug delivery technologies.